Angiogenesis in the primate ovary

被引:66
作者
Fraser, HM [1 ]
Wulff, C [1 ]
机构
[1] MRC, Human Reprod Sci Unit, Ctr Reprod Biol, Edinburgh EH3 9ET, Midlothian, Scotland
关键词
D O I
10.1071/RD01055
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The ovary is distinctive in undergoing cyclic changes in angiogenesis that play a critical role in the normal functioning of the female reproductive system. The current paper describes the use of the marmoset monkey as an in vivo model in which the cellular and molecular regulation of angiogenesis in the ovary can be investigated and the effects of manipulation of angiogenic factors elucidated. The studies are based on quantifying changes in blood vessel area and endothelial cell proliferation, monitoring changes in expression patterns of putative angiogenic regulatory factors and targeting these factors by antagonists in vivo. Quantification of endothelial cell proliferation shows that angiogenesis commences in the pre-antral follicle, increases with follicular development and becomes intense in the early corpus luteum. Vascular endothelial growth factor (VEGF), a principal angiogenic factor, is synthesized by the developing follicle and corpus luteum. Administration of specific antagonists in vivo for selected periods of the ovulatory cycle shows that inhibition of VEGF results in a marked decrease in endothelial cell proliferation in the follicle and is accompanied by a decline in granulosa cell proliferation. Inhibition during the early or mid-luteal phase results in a marked suppression in luteal angiogenesis, failure of development of the microvascular tree and suppression of luteal function. Manipulation of angiogenesis should be a novel approach to either promoting or inhibiting the normal processes of folliculogenesis, ovulation and corpus luteum function.
引用
收藏
页码:557 / 566
页数:10
相关论文
共 23 条
[1]   Inhibition of early luteal angiogenesis by gonadotropin-releasing hormone antagonist treatment in the primate [J].
Dickson, SE ;
Fraser, HM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (06) :2339-2344
[2]   Mid-luteal angiogenesis and function in the primate is dependent on vascular endothelial growth factor [J].
Dickson, SE ;
Bicknell, R ;
Fraser, HM .
JOURNAL OF ENDOCRINOLOGY, 2001, 168 (03) :409-416
[3]  
Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97
[4]   ANGIOGENESIS IN REPRODUCTIVE TISSUES [J].
FINDLAY, JK .
JOURNAL OF ENDOCRINOLOGY, 1986, 111 (03) :357-366
[5]  
FOLKMAN J, 1992, STEROID HORMONES AND UTERINE BLEEDING, P143
[6]   The effect of the angiogenesis inhibitor TNP-470 on luteal establishment and function in the primate [J].
Fraser, HM ;
Dickson, SE ;
Morris, KD ;
Erickson, GF ;
Lunn, SF .
HUMAN REPRODUCTION, 1999, 14 (08) :2054-2060
[7]   Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor [J].
Fraser, HM ;
Dickson, SE ;
Lunn, SF ;
Wulff, C ;
Morris, KD ;
Carroll, VA ;
Bicknell, R .
ENDOCRINOLOGY, 2000, 141 (03) :995-1000
[8]   Regulation and manipulation of angiogenesis in the primate corpus luteum [J].
Fraser, HM ;
Lunn, SF .
REPRODUCTION, 2001, 121 (03) :355-362
[9]   Angiogenesis and its control in the female reproductive system [J].
Fraser, HM ;
Lunn, SF .
BRITISH MEDICAL BULLETIN, 2000, 56 (03) :787-797
[10]   A quantitative study of changes in the human corpus luteum microvasculature during the menstrual cycle [J].
Gaytán, F ;
Morales, C ;
García-Pardo, L ;
Reymundo, C ;
Bellido, C ;
Sánchez-Criado, JE .
BIOLOGY OF REPRODUCTION, 1999, 60 (04) :914-919